Network analysis (NA) is a widely used computational tool for exploring the complex systems of interactions in ethnopharmacology, aiming to predict potential targets and generate mechanistic hypotheses. However, the predictive validity and biological relevance of its outputs are constrained by a pervasive methodological bottleneck: the recurrent identification of a narrow set of molecules—such as quercetin—across disparate natural products and diseases. Through a systematic analysis of 1,038 network-based studies, we establish “homogeneity” as a coherent, multi-level pattern, from “Flavonoid Centrality” to a “Hub-Target Core” and restricted “Canonical Pathways,” transcending specific remedies or diseases. We conceptualize this as a self-reinforcing “convergent discovery pipeline,” in which initial database biases are amplified by context-insensitive analytical approaches. Empirical evidence shows that integrating contextual experimental or multi-omics data mitigates homogeneity. To break this cycle and align network analysis more closely with pharmacological best practices, we propose an integrated framework that shifts from database dependency to empirically driven data acquisition, leverages bias-aware artificial intelligence for curation and prioritization, and advances dynamic, context-specific network modeling. This framework provides a clear roadmap to disrupt methodological inertia and steer network-based research in ethnopharmacology toward a more robust, diverse, and pharmacologically and clinically relevant future.
Currently, whether Hashimoto's thyroiditis decreases ovarian reserve is not clearly known, given the conflicting findings from previous studies. This study was conducted to systematically review and summarize the association of Hashimoto's thyroiditis (HT) with ovarian reserve. Studies investigating ovarian reserve in women with HT and the incidence of HT in women with premature ovarian aging (POA) were searched in major electronic databases. Pre-specified subgroup analyses were performed in terms of agedistribution and thyroidfunction. A total of 935 studies were retrieved from which 30 were included in the meta-analysis and 5 were finallyselectedfor detailed review. Overall, no statistically significant difference in ovarian reserve parameters (AMH, AFC, FSH, E2) between females with HT and the controls. In subgroup meta-analyses, reproductive aged women with HT had a statistically significant reduction in AMH (SMD -0.35; 95% CI: -0.51, -0.19; P<0.0001; I2 = 52%), AFC (MD -0.43; 95% CI: -0.56, -0.30; P<0.00001; I2 = 62%), and increase in basal FSH (SMD 0.1; 95% CI: 0.01, 0.19; I2 = 19%; P = 0.04) compared with age matched controls. Furthermore, POA inreproductive aged women wasassociatedwith higher frequency ofpositiveTPOAb (OR 2.26, 95% CI: 1.31-3.92, p = 0.004) but not positive TgAb(OR 3.17, 95% CI: 0.89-11.38, p = 0.08). These bidirectional associations suggested that reproductive aged women with HT have a significantly higher risk of diminished ovarian reserve.
Background: Thin endometrium negatively impacts the reproductive function. Current treatments for thin endometrium do not always improve endometrial receptivity. Preliminary evidence suggests that electroacupuncture could have potential therapy for thin endometrium in infertile women. Thus, this randomized controlled trial was designed to test whether electroacupuncture can improve endometrial receptivity in infertile women with thin endometrium. Methods: This study is a randomized, single-blinded, controlled, clinical trial. A total of 142 eligible patients will be recruited and randomly assigned to the electroacupuncture (EA) group or the sham electroacupuncture (SEA) group in a 1:1 ratio. Participants will receive 36 sessions over three menstrual cycles (12 weeks in total), with the same acupoint prescription. The primary outcome of this trial is endometrial thickness in the midluteal phase. The secondary outcomes include endometrial pattern, resistance index (RI) and pulsatility index (PI) of bilateral uterine artery and endometrium blood flow, serum estradiol (E2) and progesterone (P), and pregnancy rate. The pregnancy rate will be evaluated during a 6-month follow-up after completion of the trial. All other outcomes will be evaluated before treatment, during the treatment of 1st, 2nd, and 3rd menstrual cycle, and 6 months after treatment. Discussion: If the outcome confirms the effectiveness of electroacupuncture for thin endometrium in infertile women, this treatment will be proposed for application in clinical practice. Trial registration: Chinese Clinical Trials Registry ChiCTR2000029983. Registered on 18 February 2020
18 December 2025 in Frontiers in Molecular Biosciences
The ‘one-size-fits-all’ therapeutic model is inadequate to address individual patient variability, creating an urgent need for an integrative framework for precision medicine. The ‘Three Causes Tailored Treatment’ (TCTT) principle from traditional Chinese medicine offers a time-tested, holistic blueprint that simultaneously considers the individual, temporal, and environmental dimensions of health. Here, we argue that the synergy of artificial intelligence (AI) and multi-omics technologies is the key to transforming this ancient wisdom into a modern, quantitative clinical paradigm. We demonstrate how multi-omics data provides the foundational layers to quantify the TCTT principle—for instance, using integrated omics (e.g., genomics, proteomics, microbiome) to establish the individual’s molecular baseline (“Who”); chronomics to capture temporal fluxes (“When”); and the exposome to decipher the internalized environmental imprint (“Where”)—while AI-powered multimodal integration models their complex interactions. By synthesizing evidence across the disease continuum, this review provides a translational roadmap for building dynamic clinical decision-support systems, thereby charting a course toward truly personalized, time-sensitive, and context-aware healthcare.
Background: The incidence of male infertility is increasing in recent years, and the semen routine examination of some patients is normal, but the semen pathological examination shows that the sperm DNA fragmentation index (DFI) is high, and the patients’ clinical manifestations are infertility or recurrent abortion of their spouses. At present, there is no special treatment for male infertility caused by high DFI, and traditional Chinese medicine compound prescription shows potential value in the treatment of male infertility. Wuwei Fuzheng Yijing formula (WFY) is an effective prescription for the treatment of sperm DNA damage in male infertility, but there is no strict clinical trial to support its application. Therefore, we designed a randomized controlled trial to evaluate the efficacy and safety of WFY in patients with sperm DNA damage in male infertility. Methods: In this randomized controlled study, 100 patients who met the inclusion criteria were randomly divided into WFY group and levocarnitine oral solution group. The treatment period was 12 weeks. The main observation index was sperm DFI, and the secondary observation index was sperm concentration, motility, survival rate, and TCM syndrome score. Safety observation indicators will include electrocardiogram, blood tests (including blood routine tests, liver and renal function), routine urine tests, and routine stool tests. All results were evaluated at the 4th and 8th week of the baseline, and the end of treatment. Discussion: This study will provide a basis for the efficacy and safety of WFY in the treatment of sperm DNA damage in male infertility with spleen and kidney qi deficiency and blood stasis.
29 September 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology